COMMUNIQUÉS West-GlobeNewswire

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
07/07/2026
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory [...]
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
07/07/2026
C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the [...]
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
07/07/2026
NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers [...]
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
07/07/2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to [...]
Glass House Brands Completes First International Hemp Sale
07/07/2026
LONG BEACH, Calif. and TORONTO, July 07, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (NYSE: GLAS) today announced the completion of its first international sale [...]
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
07/07/2026
Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the US Kaleio to support brand strategies and customized [...]
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
07/07/2026
Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company [...]
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
07/07/2026
Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, [...]
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
07/07/2026
Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data I ntroduces a first-of-its-kind [...]
Transactions in connection with share buy-back program
07/07/2026
Company announcement no. 24 - 26 7 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Levicept Appoints Darlene Deptula-Hicks as CFO
07/07/2026
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis SANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a [...]
EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
07/07/2026
GLASGOW, Scotland, July 07, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EnteroBiotix”), a clinical-stage biopharmaceutical company developing orally delivered full-spectrum microbiome therapeutics for [...]
Rapid Nutrition Showcases HealthTech Strategy on Bloomberg Television
07/07/2026
Interview showcases the Company's implementation of intelligent technologies across consumer wellness and investor engagement, reinforcing its evolution into a scalable HealthTech platform LONDON, July 06, 2026 (GLOBE [...]
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
07/07/2026
Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle TM AD study and design of Phase III PrevenTRON study in preclinical [...]
Clareo Plastic Surgery Named Best Plastic Surgery Practice in Boston
06/07/2026
Cliche Magazine Recognizes Clareo for Excellence in Cosmetic Procedures Chestnut Hill, MA, July 06, 2026 (GLOBE NEWSWIRE) -- Clareo Plastic Surgery has been honored as the best plastic surgery practice in Boston, [...]
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06/07/2026
Media Release COPENHAGEN, Denmark; July 6, 2026 TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2 ) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma [...]
Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
06/07/2026
CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
Alberta Cancer Foundation invests $35-million to power cancer clinical trials for Albertans
06/07/2026
Historic funding over the next five years strengthens Alberta’s newly launched 10-Year Cancer Care Strategy CALGARY, Alberta, July 06, 2026 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is investing $35-million to [...]
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
06/07/2026
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) [...]

Pages